Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Departments of Dermatology, Baylor College of Medicine and Veterans Affairs Medical Center Houston, Texas, USA.
A clinically refractory case of cutaneous sarcoidosis was successfully treated with infliximab infusion therapy at a dose of 5mg/kg. Skin lesions cleared dramatically and remain resolved during a 3(1/2) year follow-up, the longest follow-up reported to date. Ongoing biological drug therapy has been administered at a frequency of every 8-10 weeks. Despite cost and safety concerns, infliximab should be considered in cases of cutaneous sarcoidosis refractory to standard treatment protocols.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on